Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Axsome Therapeutics

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

Benzinga

Stocks Showing Rising Market Leadership: Axsome Therapeutics Earns 83 RS Rating

Axsome Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 83.

Investors Business Daily

Stocks Showing Rising Market Leadership: Axsome Therapeutics Earns 82 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 66 to 82.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Axsome Therapeutics Trying To Close In On Key Technical Measure

Axsome Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

IBD Rating Upgrades: Axsome Therapeutics Shows Improved Relative Price Strength

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Stocks Generating Improved Relative Strength: Axsome Therapeutics

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Investors Business Daily

Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Investors Business Daily

Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts

Axsome expects its eight products to generate up to $11.5 billion in peak U.S. sales. AXSM stock zoomed higher Wednesday.

Investors Business Daily

Dow Jones Dips As Zscaler Rockets; Three Warren Buffett Stocks Near Entries As Berkshire Gains

The Dow Jones was flat. Disney stock rose amid further escalation in its Ron DeSantis fight. A trio of Warren Buffett stocks neared entries.

Investors Business Daily

Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.

Axsome and BioXcel issued divergent earnings reports Monday, but BTAI stock reversed an earlier dive and rose alongside AXSM stock.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Royal Caribbean Cruises

Read news from The Economist, FT, and more,
with one subscription

Places

Fla

2,924 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.